Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinsons Disease
Event to be held October 14th at 4 p.m. EST October 09,…
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety…
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
October 05, 2025 09:00 ET Â | Source: Spyre Therapeutics, Inc. WALTHAM, Mass.,…
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025 16:01 ET Â | Source: Intellia Therapeutics, Inc. CAMBRIDGE, Mass.,…
Artelo Biosciences Announces Proposed Underwritten Public Offering
September 29, 2025 19:15 ET Â | Source: Artelo Biosciences SOLANA BEACH, Calif.,…
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX),…
ORYZON to Participate in Upcoming Events in September and October
September 25, 2025 08:00 ET Â | Source: Oryzon Genomics, S.A. MADRID and…
Halia Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
LEHI, Utah, Sept. 4, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage…
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
September 02, 2025 21:33 ET Â | Source: Mineralys Therapeutics, Inc. RADNOR, Pa.,…
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq:…